| Accession | ARO:3004562 |
| CARD Short Name | Cdif_gyrB_FLO |
| Definition | Point mutations in gyrB of Clostridioides difficile conferring resistance to fluoroquinolone antibiotics. |
| AMR Gene Family | fluoroquinolone resistant gyrB |
| Drug Class | fluoroquinolone antibiotic |
| Resistance Mechanism | antibiotic target alteration |
| Resistomes with Sequence Variants | Clostridium botulinumg+wgs, Clostridium butyricumg+wgs, Clostridium sporogenesg+wgs, Clostridium tetanig+wgs |
| Classification | 11 ontology terms | Show + process or component of antibiotic biology or chemistry + mechanism of antibiotic resistance + antibiotic target alteration [Resistance Mechanism] + determinant of antibiotic resistance + mutation conferring antibiotic resistance + antibiotic resistant gene variant or mutant + antibiotic molecule + antibiotic resistant DNA topoisomerase subunit + fluoroquinolone antibiotic [Drug Class] + fluoroquinolone resistant DNA topoisomerase + antibiotic resistant DNA topoisomerase subunit gyrB |
| Parent Term(s) | 5 ontology terms | Show + fluoroquinolone resistant gyrB [AMR Gene Family] + confers_resistance_to_antibiotic ciprofloxacin [Antibiotic] + confers_resistance_to_antibiotic moxifloxacin [Antibiotic] + confers_resistance_to_antibiotic levofloxacin [Antibiotic] + confers_resistance_to_antibiotic gemifloxacin [Antibiotic] |
| Publications | Dridi L, et al. 2002. Antimicrob. Agents Chemother. 46(11):3418-21 gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. (PMID 12384345) Walkty A, et al. 2010. Diagn. Microbiol. Infect. Dis. 66(4):419-24 Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. (PMID 20226332) Spigaglia P, et al. 2008. J. Med. Microbiol. 57(Pt 6):784-9 Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. (PMID 18480338) Liao CH, et al. 2012. Antimicrob. Agents Chemother. 56(7):3943-9 Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. (PMID 22508299) Mac Aogáin M, et al. 2015. J Glob Antimicrob Resist 3(4):295-299 Identification of a novel mutation at the primary dimer interface of GyrA conferring fluoroquinolone resistance in Clostridium difficile. (PMID 27842877) |
Prevalence of Clostridioides difficile gyrB conferring resistance to fluoroquinolones among the sequenced genomes, plasmids, and whole-genome shotgun assemblies available at NCBI or IslandViewer for 413 important pathogens (see methodological details and complete list of analyzed pathogens). Values reflect percentage of genomes, plasmids, genome islands, or whole-genome shotgun assemblies that have at least one hit to the AMR detection model. Default view includes percentages calculated based on Perfect plus Strict RGI hits. Select the checkbox to view percentages based on only Perfect matches to AMR reference sequences curated in CARD (note: this excludes resistance via mutation as references in protein variant models are often wild-type, sensitive sequences).
| Species | NCBI Chromosome | NCBI Plasmid | NCBI WGS | NCBI GI |
|---|---|---|---|---|
| Clostridium botulinum | 97.01% | 0% | 56.79% | 0% |
| Clostridium butyricum | 66.67% | 0% | 82.35% | 0% |
| Clostridium sporogenes | 100% | 0% | 91.45% | 0% |
| Clostridium tetani | 50% | 0% | 100% | 0% |
Model Type: protein variant model
Model Definition: Protein Variant Models (PVM) perform a similar search as Protein Homolog Models (PHM), i.e. detect protein sequences based on their similarity to a curated reference sequence, but secondarily screen query sequences for curated sets of mutations to differentiate them from antibiotic susceptible wild-type alleles. PVMs are designed to detect AMR acquired via mutation of house-keeping genes or antibiotic targets, e.g. a mutated gyrase resistant to aminocoumarin antibiotics. PVMs include a protein reference sequence (often from antibiotic susceptible wild-type alleles), a curated bit-score cut-off, and mapped resistance variants. Mapped resistance variants may include any or all of single point mutations, insertions, or deletions curated from the scientific literature. A Strict RGI match has a BLASTP bit-score above the curated BLASTP cutoff value and contains at least one curated mutation from amongst the mapped resistance variants, while a Loose RGI match has a bit-score less than the curated BLASTP bit-score cut-off but still contains at least one curated mutation from amongst the mapped resistance variants.
Bit-score Cut-off (blastP): 1000
Legend:
Published Variants:
| PMID: 12384345 | D426N R447L |
| PMID: 20226332 | K444F E466V |
| PMID: 18480338 | S416A D426V R447K |
| PMID: 22508299 | R377G R389P E399K D409N V423F R457T D465Y E466K |
| PMID: 27842877 | V130I I139R S366V S366A S464T |